Skip to main content
Biocartis Group NV logo

Biocartis Group NV — Investor Relations & Filings

Ticker · BCART ISIN · BE0974281132 LEI · 549300J4HOJL5KG8HY54 BR Manufacturing
Open in API
Filings indexed 636 across all filing types
Latest filing 2020-11-24 Director's Dealing
Country BE Belgium
Listing BR BCART

About Biocartis Group NV

https://www.biocartis.com/en

Biocartis Group NV is a molecular diagnostics company that develops and commercializes its proprietary Idylla™ platform. This fully automated, sample-to-result system is designed to provide fast, easy, and actionable molecular diagnostic results, making advanced testing accessible to laboratories of any size. The company's primary focus is in the field of oncology, offering a menu of tests that support the diagnosis and treatment of various cancers, including lung, colorectal, melanoma, and breast cancer. Biocartis aims to enable personalized medicine for patients by providing universal access to molecular testing. The company also collaborates with pharmaceutical partners in the development of companion diagnostics.

Recent filings

Filing Released Lang Actions
201124_pr_transparency_debio_eng_final.pdf
Director's Dealing Classification · 98% confidence The document is explicitly titled "PRESS RELEASE REGULATED INFORMATION" and details the receipt of a "transparency notification" regarding a change in major shareholdings (Debiopharm Innovation Fund S.A. falling below the 3% threshold) as required by the Belgian Transparency Act. This type of filing, which reports changes in significant ownership stakes by individuals or entities, directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is presented as a press release, the core content is the disclosure of a major shareholding change.
2020-11-24 English
201124_pr_transparency_debio_nl_final.pdf
Major Shareholding Notification Classification · 98% confidence The document is a formal announcement in Dutch titled "Openbaarmaking van een transparantiekennisgeving" (Disclosure of a transparency notification). It explicitly states that the company received a notification regarding a change in shareholding percentage (Debiopharm Innovation Fund S.A. falling below the 3% threshold) as required by the Belgian Transparency Law. This type of filing, which reports changes in significant share ownership or insider transactions, aligns best with the 'Major Shareholding Notification' category (MRQ) or potentially 'Director's Dealing' (DIRS) if the shareholder was a director, but since it details crossing a statutory ownership threshold (3%), MRQ is the most precise fit among the provided options. It is not an earnings release, annual report, or proxy statement.
2020-11-24 Dutch
201111 Biocartis Q3 2020 Business Update_ENG_FINAL.pdf
Earnings Release Classification · 99% confidence The document is explicitly titled "BIOCARTIS Q3 2020 BUSINESS UPDATE" and is dated November 12, 2020. It provides a detailed review of commercial highlights, test menu progress, partnerships, and financial highlights for the third quarter (Q3 2020), concluding with an outlook for the full year 2020. This structure—a comprehensive report covering a period shorter than a full year (quarterly) with detailed operational and financial metrics—aligns perfectly with the definition of an Interim / Quarterly Report (IR). It is not a brief announcement of a report (RPA/RNS), nor is it the full Annual Report (10-K). Q3 2020
2020-11-12 English
201111 Biocartis Q3 2020 Business Update_NL_FINAL.pdf
Management Reports Classification · 95% confidence The document is a 'Business Update' for Q3 2020 issued by Biocartis. It provides a detailed narrative of commercial, operational, and partnership highlights, as well as financial highlights (cash position). While it contains financial data, it is a periodic business update rather than a full interim financial report (which would include comprehensive financial statements). It is not an announcement of a report (RPA) because it contains the substantive content itself. It fits best under 'Management Reports' (MDA) as it provides management's detailed explanation of business trends, operational performance, and outlook for the period. Q3 2020
2020-11-12 Dutch
Biocartis and Exact Sciences Agree to End Collaboration Due to Changed Market Circumstances
Regulatory Filings Classification · 95% confidence The document is a press release dated October 29, 2020, announcing the termination of a collaboration agreement between Biocartis and Exact Sciences/Genomic Health, including details about a settlement payment and asset transfer. This type of announcement, which details a significant business event (termination of a partnership and associated financial settlement) released via a press release format, does not fit neatly into the specific financial reporting categories (like 10-K, IR, ER, or DIV). It is a general corporate update regarding business operations and legal/contractual matters. Since it is not a standard regulatory filing form, nor a specific report type like an Audit Report (AR) or Earnings Release (ER), the most appropriate classification is the general regulatory announcement fallback category, RNS (Regulatory Filings), as it serves as a broad communication to the market about a material event.
2020-10-29 English
Biocartis en Exact Sciences beëindigen samenwerking omwille van gewijzigde marktomstandigheden
Regulatory Filings Classification · 95% confidence The document is a press release dated October 29, 2020, announcing the termination of a collaboration agreement between Biocartis and Genomic Health/Exact Sciences. It details the business decision, the financial settlement (USD 12 million payment), and includes standard boilerplate information about the company and forward-looking statements. This type of announcement, which communicates a significant business event, partnership change, or legal settlement outside of routine financial reporting (like earnings or annual reports), typically falls under general regulatory announcements or news releases. Since it is not a formal financial report (10-K, IR, ER, MRQ) nor a specific corporate action like a dividend (DIV) or management change (MANG), the most appropriate classification is the general regulatory announcement category, RNS, as it serves as a broad disclosure to the market.
2020-10-29 Dutch

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.